Actio is advancing two lead rare disease programs – ABS-0871 and ABS-1230 – with first-in-class potential for the treatment of Charcot-Marie-Tooth disease, type 2C (CMT2C) and KCNT1-related ...

The U.S. FDA has cleared Actio Biosciences Inc.’s IND application and granted fast track designation to ABS-1230, an expected first-in-class, orally administered small-molecule KCNT1 inhibitor, for ...